首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >97%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL-33 |
| Uniprot No | O95760 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 112-270aa |
| 氨基酸序列 | SITGISPIT EYLASLSTYN DQSITFALED ESYEIYVEDL KKDEKKDKVLLSYYESQHPS NE SGDGVDGK MLMVTLSPTK DFWLHANNKE HSVELHKCEKPLPDQAFFVL HNMHSNCVSF ECKTDPGVFI GVKDNHLALI KVDSSENLCT ENILFKLSET |
| 预测分子量 | 17.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL-33重组蛋白的3篇代表性文献，简要整理如下：
---
1. **文献名称**: *IL-33. an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines*
**作者**: Schmitz, J. et al.
**摘要**: 该研究首次报道了IL-33作为IL-1家族的新成员，可通过受体ST2激活免疫细胞(如Th2细胞)，促进IL-4、IL-5等细胞因子分泌，参与过敏和抗寄生虫免疫反应。文中还描述了重组IL-33蛋白的制备及其功能验证。
---
2. **文献名称**: *IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation*
**作者**: Liew, F.Y. et al.
**摘要**: 通过动物模型证明，重组IL-33蛋白能直接激活先天免疫细胞(如肥大细胞)和适应性免疫细胞，增强Th2型免疫应答，加剧哮喘等过敏性气道炎症，提示IL-33在过敏性疾病中的潜在治疗靶点作用。
---
3. **文献名称**: *IL-33 promotes influenza-induced lung neutrophilia and antiviral T cell responses*
**作者**: Martin, N.T. et al.
**摘要**: 研究利用重组IL-33蛋白处理流感病毒感染小鼠，发现其通过增强肺部中性粒细胞募集和抗病毒T细胞反应，减轻病毒载量并改善生存率，揭示了IL-33在抗病毒感染中的双重免疫调节功能。
---
4. **文献名称**: *Structural characterization of human IL-33 and its interaction with the ST2 receptor*
**作者**: Carriere, V. et al.
**摘要**: 通过X射线晶体学解析了重组IL-33蛋白的结构，阐明了其与受体ST2结合的分子机制，并发现其C端核定位序列的缺失可增强体外生物活性，为靶向IL-33/ST2通路的药物设计提供结构基础。
---
以上文献涵盖了IL-33重组蛋白的发现、结构、免疫调控机制及疾病相关研究。如需具体期刊信息或年份，可进一步补充。
Interleukin-33 (IL-33), a member of the interleukin-1 (IL-1) cytokine family, is a dual-function protein that acts both as a nuclear transcription regulator and an extracellular alarmin. Discovered in 2005. IL-33 is constitutively expressed in epithelial and endothelial cells of barrier tissues, where it remains stored in the nucleus under homeostatic conditions. Upon cellular stress or damage, it is released into the extracellular space to signal through its receptor complex, composed of ST2 (IL-1RL1) and IL-1 receptor accessory protein (IL-1RAcP), triggering downstream pro-inflammatory signaling pathways like NF-κB and MAPK. This activation promotes type 2 immune responses, involving Th2 cells, mast cells, and eosinophils, which are critical in allergic inflammation, parasitic immunity, and tissue repair.
Recombinant IL-33 proteins are engineered versions produced via heterologous expression systems, typically in *E. coli* or mammalian cells, to ensure proper folding and bioactivity. These proteins are widely used in research to study IL-33/ST2 signaling mechanisms, model allergic diseases (e.g., asthma, atopic dermatitis), and explore fibrotic or autoimmune conditions. The recombinant form often includes the mature bioactive domain (aa 109-270 in humans), as full-length IL-33 requires proteolytic processing (e.g., by caspases or mast cell proteases) to become active.
Clinically, IL-33 is implicated as a therapeutic target, with inhibitors (e.g., anti-ST2 antibodies) in development for asthma and other type 2-driven pathologies. Conversely, recombinant IL-33 itself is investigated for its potential in enhancing mucosal immunity or tissue regeneration. Its dual role—balancing pro-inflammatory and tissue-protective effects—underscores its complexity in health and disease, driving ongoing research to harness or modulate its activity for therapeutic benefit.
×
